Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
13.52
+0.29 (2.19%)
At close: Jun 26, 2026, 4:00 PM EDT
13.73
+0.21 (1.56%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 28.25, with a low estimate of 21 and a high estimate of 35. The average target predicts an increase of 108.95% from the current stock price of 13.52.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 24, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $26 | Buy | Reiterates | $26 | +92.31% | Jun 23, 2026 |
| Maxim Group | Maxim Group | Buy Reiterates $25 → $35 | Buy | Reiterates | $25 → $35 | +158.88% | Jun 10, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +114.50% | Jun 10, 2026 |
| BTIG | BTIG | Buy Reiterates $23 → $27 | Buy | Reiterates | $23 → $27 | +99.70% | Jun 9, 2026 |
Financial Forecast
Revenue This Year
145.74M
from 106.47M
Increased by 36.88%
Revenue Next Year
182.24M
from 145.74M
Increased by 25.05%
EPS This Year
1.22
from 1.35
Decreased by -9.38%
EPS Next Year
1.20
from 1.22
Decreased by -2.32%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 164.0M | 228.2M | |
| Avg | 145.7M | 182.2M | |
| Low | 135.4M | 154.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 54.0% | 56.6% | |
| Avg | 36.9% | 25.0% | |
| Low | 27.2% | 6.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.31 | 1.51 | |
| Avg | 1.22 | 1.20 | |
| Low | 1.17 | 0.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.0% | 23.4% | |
| Avg | -9.4% | -2.3% | |
| Low | -13.3% | -32.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.